Islam Khalid 4

What Happened

• Islam Khalid, a director of Fennec Pharmaceuticals (FENC), was granted a non‑qualified stock option to purchase 25,000 common shares. The option has a strike price of $8.70 per share, which corresponds to a strike/contract value of $217,500. This was an award/grant (derivative) on June 10, 2026 — it is a compensation grant, not an immediate sale or open‑market purchase.

Key Details

• Transaction date: 2026-06-10. Filing date: 2026-06-10 (filed timely).
• Option terms: 25,000-share non‑qualified stock option, $8.70 strike price; total strike value reported $217,500.
• Vesting: The option is 100% vested on the date of grant (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 confirms the NQSO grant under the issuer’s Equity Incentive Plan; F2 confirms immediate 100% vesting.
• Filing timeliness: No late filing indicated.

Context

• This is a grant of an option (a derivative right to buy shares in the future) rather than an exercise or sale. Because it’s an option grant, no new shares were reported as issued or sold at the time of the filing; the holder can exercise the option later (immediately, given full vesting) by paying the $8.70 strike per share.
• The reported $217,500 reflects the strike price times shares, not the intrinsic or market value. The filing does not state whether the holder plans to exercise, sell, or hold the shares.